Retrophin (NASDAQ:RTRX) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. “

A number of other equities research analysts have also recently issued reports on the stock. ValuEngine cut shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. BMO Capital Markets reiterated a “buy” rating and set a $44.00 target price on shares of Retrophin in a research report on Friday, October 6th. Finally, BidaskClub cut shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Saturday, December 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $44.00.

Shares of Retrophin (RTRX) traded up $1.27 during trading on Thursday, hitting $23.74. 503,600 shares of the company were exchanged, compared to its average volume of 425,200. The firm has a market cap of $883.22, a PE ratio of -15.72 and a beta of 0.96. The company has a quick ratio of 3.83, a current ratio of 3.88 and a debt-to-equity ratio of 0.15. Retrophin has a 1-year low of $15.55 and a 1-year high of $26.44.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.21). The firm had revenue of $40.34 million for the quarter, compared to analyst estimates of $40.51 million. Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The company’s revenue for the quarter was up 18.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.09) EPS. equities analysts predict that Retrophin will post -1.25 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC increased its position in Retrophin by 1.8% in the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 146 shares in the last quarter. Ameriprise Financial Inc. increased its position in Retrophin by 1.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 30,520 shares of the biopharmaceutical company’s stock valued at $592,000 after acquiring an additional 290 shares in the last quarter. Legal & General Group Plc increased its position in Retrophin by 4.3% in the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 355 shares in the last quarter. AJO LP increased its position in Retrophin by 1.9% in the 2nd quarter. AJO LP now owns 59,681 shares of the biopharmaceutical company’s stock valued at $1,157,000 after acquiring an additional 1,094 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in Retrophin by 3.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,471 shares of the biopharmaceutical company’s stock valued at $649,000 after acquiring an additional 1,200 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2018/01/04/zacks-investment-research-upgrades-retrophin-rtrx-to-hold.html.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.